Skip to content

Drug interactions

Imatinib + Venetoclax

Severity: Major

Imatinib and Venetoclax: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Imatinib may raise venetoclax concentrations through CYP3A4 inhibition. Higher exposure increases the risk of tumor lysis syndrome during ramp-up and of neutropenia. Moderate CYP3A inhibitors require venetoclax dose reduction.

What this interaction means in plain words

Imatinib and Venetoclax can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Imatinib belongs to Oncology; Venetoclax belongs to Miscellaneous.

Evidence level: Moderate

Why it happens

Imatinib inhibits CYP3A4, decreasing venetoclax clearance.

What to do

Reduce the venetoclax dose by at least 50% when coadministered with a moderate CYP3A inhibitor. Monitor closely for tumor lysis syndrome and neutropenia.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Imatinib and Venetoclax, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Imatinib with Venetoclax?

MediHelp rates the interaction as major. Imatinib and Venetoclax can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Imatinib may raise venetoclax concentrations through CYP3A4 inhibition. Higher exposure increases the risk of tumor lysis syndrome during ramp-up and of neutropenia. Moderate CYP3A inhibitors require venetoclax dose reduction.

How serious is the interaction between Imatinib and Venetoclax?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Reduce the venetoclax dose by at least 50% when coadministered with a moderate CYP3A inhibitor. Monitor closely for tumor lysis syndrome and neutropenia.

What other medicines interact with Imatinib?

MediHelp also lists interactions of Imatinib with, for example, Lomitapide, Lonafarnib, Amobarbital. The full list is on the Imatinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in